Refine
Has Fulltext
- yes (24)
Year of publication
Document Type
- Journal article (24)
Language
- English (24)
Keywords
- cancer (3)
- chronic myeloid leukemia (2)
- lung cancer (2)
- transcription (2)
- ABL gene (1)
- ALS treatment (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Bombus Spp. Hymenoptera (1)
- CML (1)
- COX2 expression (1)
- CRISPR-Cas9 (1)
- Cancer (1)
- Chronic myeloid leukaemia (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Human behaviour (1)
- JUN (1)
- MYC (1)
- Mexican coffee plantations (1)
- Molecularly targeted therapy (1)
- NRF2 (1)
- Northeastern Costa Rica (1)
- Personalized medicine (1)
- Prognostic markers (1)
- Psychiatric disorders (1)
- RQQ domain (1)
- Risk factors (1)
- T1 (1)
- Translational research (1)
- achaete-scute homolog 1 (1)
- allogeneic hematopoietic stem cell transplantation (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anti-infective vaccination (1)
- antimicrobial (1)
- antimicrobial responses (1)
- anxiety (1)
- aquaporin 3 protein (1)
- assistive devices (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- autophagy (1)
- bacillus calmette guerin (1)
- binding protein (1)
- bird species richness (1)
- breakpoint (1)
- bumblebee nest density (1)
- cancer genomics (1)
- cancer metabolism (1)
- caregiver burden (1)
- cell biology (1)
- chemotypes (1)
- chronic myelogenous leukemia (1)
- chronic phase (1)
- clinical genetics (1)
- coating (1)
- collections (1)
- complex (1)
- cuticular hydrocarbons (1)
- cytogenetic response (1)
- c‐Myc (1)
- data sharing (1)
- decay (1)
- decreasing autonomy (1)
- deep sea neutrino telescope (1)
- degradation (1)
- depression (1)
- different imatinib dose regimens (1)
- distribution (1)
- drug treatment (1)
- dry-mounted samples (1)
- dung beetle coleoptera (1)
- early applied higher imatinib dosages (1)
- eutrino physics (1)
- follow up (1)
- functional status (1)
- global change (1)
- growth (1)
- habitat destruction (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- herpes virus (1)
- hybrid messenger RNA (1)
- identification (1)
- immunogenetics (1)
- immunohistochemistry (1)
- immunosuppression (1)
- implant (1)
- in vitro (1)
- infection (1)
- informal caregiving (1)
- instensively managed farmland (1)
- land use (1)
- land-use change (1)
- large gene lists (1)
- mechanisms of disease (1)
- melanoma malignancy (1)
- metastasis (1)
- motifs (1)
- mouse model (1)
- neurogenic locus notch homolog (1)
- neutrino astronomy (1)
- neutrino mass hierarchy (1)
- no correlation (1)
- non-small cell lung cancer (1)
- older patients (1)
- oncogenesis (1)
- osteogenic (1)
- paediatric cancer (1)
- plant community composition (1)
- polymerase-chain-reaktion (1)
- predictive markers (1)
- pro-angiogenic (1)
- progression (1)
- proliferation (1)
- protein biosynthesis & quality control (1)
- psychiatric disorders (1)
- psychological support (1)
- quality of life (QoL) (1)
- recurrence (1)
- retinoblastoma protein (1)
- small cell lung cancer (1)
- socioeconomic status (1)
- stage pT1 (1)
- stem cell transplantation (1)
- stress (1)
- survival (1)
- symptom-specific treatment (1)
- titanium (1)
- transcriptional responses (1)
- transcripts (1)
- transformation (1)
- transitional cell carcinoma (1)
- translational regulation (1)
- translational research (1)
- tumor (1)
- tyrosine kinase inhibitors (1)
- urban-rural gradient (1)
- urothelial bladder carcinoma (1)
- water channels (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (10)
- Medizinische Klinik und Poliklinik II (7)
- Institut für Virologie und Immunbiologie (3)
- Institut für Psychologie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Medizinische Klinik und Poliklinik I (2)
- Neurologische Klinik und Poliklinik (2)
- Pathologisches Institut (2)
- Comprehensive Cancer Center Mainfranken (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
Sonstige beteiligte Institutionen
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients remains low, demonstrating the necessity for novel treatments. One strategy to improve translational research is the development of surrogate models reflecting somatic mutations identified in lung cancer patients as these impact treatment responses. With the advent of CRISPR-mediated genome editing, gene deletion as well as site-directed integration of point mutations enabled us to model human malignancies in more detail than ever before. Here, we report that by using CRISPR/Cas9-mediated targeting of Trp53 and KRas, we recapitulated the classic murine NSCLC model Trp53fl/fl:lsl-KRasG12D/wt. Developing tumors were indistinguishable from Trp53fl/fl:lsl-KRasG12D/wt-derived tumors with regard to morphology, marker expression, and transcriptional profiles. We demonstrate the applicability of CRISPR for tumor modeling in vivo and ameliorating the need to use conventional genetically engineered mouse models. Furthermore, tumor onset was not only achieved in constitutive Cas9 expression but also in wild-type animals via infection of lung epithelial cells with two discrete AAVs encoding different parts of the CRISPR machinery. While conventional mouse models require extensive husbandry to integrate new genetic features allowing for gene targeting, basic molecular methods suffice to inflict the desired genetic alterations in vivo. Utilizing the CRISPR toolbox, in vivo cancer research and modeling is rapidly evolving and enables researchers to swiftly develop new, clinically relevant surrogate models for translational research.
Improving quality of life (QoL) is central to amyotrophic lateral sclerosis (ALS) treatment. This Germany-wide, multicenter cross-sectional study analyses the impact of different symptom-specific treatments and ALS variants on QoL. Health-related QoL (HRQoL) in 325 ALS patients was assessed using the Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) and EuroQol Five Dimension Five Level Scale (EQ-5D-5L), together with disease severity (captured by the revised ALS Functional Rating Scale (ALSFRS-R)) and the current care and therapies used by our cohort. At inclusion, the mean ALSAQ-5 total score was 56.93 (max. 100, best = 0) with a better QoL associated with a less severe disease status (β = −1.96 per increase of one point in the ALSFRS-R score, p < 0.001). “Limb-onset” ALS (lALS) was associated with a better QoL than “bulbar-onset” ALS (bALS) (mean ALSAQ-5 total score 55.46 versus 60.99, p = 0.040). Moreover, with the ALSFRS-R as a covariate, using a mobility aid (β = −7.60, p = 0.001), being tracheostomized (β = −14.80, p = 0.004) and using non-invasive ventilation (β = −5.71, p = 0.030) were associated with an improved QoL, compared to those at the same disease stage who did not use these aids. In contrast, antidepressant intake (β = 5.95, p = 0.007), and increasing age (β = 0.18, p = 0.023) were predictors of worse QoL. Our results showed that the ALSAQ-5 was better-suited for ALS patients than the EQ-5D-5L. Further, the early and symptom-specific clinical management and supply of assistive devices can significantly improve the individual HRQoL of ALS patients. Appropriate QoL questionnaires are needed to monitor the impact of treatment to provide the best possible and individualized care.
Coordinated regulation of the lysosomal and autophagic systems ensures basal catabolism and normal cell physiology, and failure of either system causes disease. Here we describe an epigenetic rheostat orchestrated by c-MYC and histone deacetylases that inhibits lysosomal and autophagic biogenesis by concomitantly repressing the expression of the transcription factors MiT/TFE and FOXH1, and that of lysosomal and autophagy genes. Inhibition of histone deacetylases abates c-MYC binding to the promoters of lysosomal and autophagy genes, granting promoter occupancy to the MiT/TFE members, TFEB and TFE3, and/or the autophagy regulator FOXH1. In pluripotent stem cells and cancer, suppression of lysosomal and autophagic function is directly downstream of c-MYC overexpression and may represent a hallmark of malignant transformation. We propose that, by determining the fate of these catabolic systems, this hierarchical switch regulates the adaptive response of cells to pathological and physiological cues that could be exploited therapeutically.
Myc coordinates transcription and translation to enhance transformation and suppress invasiveness
(2015)
c‐Myc is one of the major human proto‐oncogenes and is often associated with tumor aggression and poor clinical outcome. Paradoxically, Myc was also reported as a suppressor of cell motility, invasiveness, and metastasis. Among the direct targets of Myc are many components of the protein synthesis machinery whose induction results in an overall increase in protein synthesis that empowers tumor cell growth. At present, it is largely unknown whether beyond the global enhancement of protein synthesis, Myc activation results in translation modulation of specific genes. Here, we measured Myc‐induced global changes in gene expression at the transcription, translation, and protein levels and uncovered extensive transcript‐specific regulation of protein translation. Particularly, we detected a broad coordination between regulation of transcription and translation upon modulation of Myc activity and showed the connection of these responses to mTOR signaling to enhance oncogenic transformation and to the TGFβ pathway to modulate cell migration and invasiveness. Our results elucidate novel facets of Myc‐induced cellular responses and provide a more comprehensive view of the consequences of its activation in cancer cells.